tetano
Editor, Senior Moderator
J Intensive Care Med
. 2023 Jun 12;8850666231180165.
doi: 10.1177/08850666231180165. Online ahead of print. Severe SARS-CoV-2 Pneumonia and Pneumomediastinum/Pneumothorax: A Prospective Observational Study in an Intermediate Respiratory Care Unit
Miguel Lorente-González[SUP] 1 [/SUP], José Rafael Terán-Tinedo[SUP] 1 [/SUP], Annette Zevallos-Villegas[SUP] 1 [/SUP], Daniel Laorden[SUP] 1 [/SUP], Pablo Mariscal-Aguilar[SUP] 1 [/SUP], Miguel Suárez-Ortiz[SUP] 1 [/SUP], Eduardo Cano-Sanz[SUP] 2 [/SUP], María Ángeles Ortega-Fraile[SUP] 2 [/SUP], Joaquín Hernández-Núñez[SUP] 2 [/SUP], Adalgisa Falcone[SUP] 1 [/SUP], Elena María Saiz-Lou[SUP] 3 [/SUP], María Cristina Plaza-Moreno[SUP] 1 [/SUP], Christian García-Fadul[SUP] 1 [/SUP], Manuel Valle-Falcones[SUP] 1 [/SUP], Ana Sánchez-Azofra[SUP] 1 [/SUP], Clotilde Funes-Moreno[SUP] 4 [/SUP], Isabel De-La-Calle-Gil[SUP] 4 [/SUP], Rosalía Navarro-Casado[SUP] 4 [/SUP], Daniel Carballo-López[SUP] 4 [/SUP], Soraya Gholamian-Ovejero[SUP] 4 [/SUP], Berta Gallego-Rodríguez[SUP] 4 [/SUP], Tomás Villén-Villegas[SUP] 2 [/SUP], Pedro Landete[SUP] 1 5 [/SUP]
Affiliations
Introduction: The occurrence of pneumomediastinum (PM) and/or pneumothorax (PTX) in patients with severe pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was evaluated.
Methods: This was a prospective observational study conducted in patients admitted to the intermediate respiratory care unit (IRCU) of a COVID-19 monographic hospital in Madrid (Spain) between December 14, 2020 and September 28, 2021. All patients had a diagnosis of severe SARS-CoV-2 pneumonia and required noninvasive respiratory support (NIRS): high-flow nasal cannula (HFNC), continuous positive airway pressure (CPAP), and bilevel positive airway pressure (BiPAP). The incidences of PM and/or PTX, overall and by NIRS, and their impact on the probabilities of invasive mechanical ventilation (IMV) and death were studied.
Results: A total of 1306 patients were included. 4.3% (56/1306) developed PM/PTX, 3.8% (50/1306) PM, 1.6% (21/1306) PTX, and 1.1% (15/1306) PM + PTX. 16.1% (9/56) of patients with PM/PTX had HFNC alone, while 83.9% (47/56) had HFNC + CPAP/BiPAP. In comparison, 41.7% (521/1250) of patients without PM and PTX had HFNC alone (odds ratio [OR] 0.27; 95% confidence interval [95% CI] 0.13-0.55; p < .001), while 58.3% (729/1250) had HFNC + CPAP/BiPAP (OR 3.73; 95% CI 1.81-7.68; p < .001). The probability of needing IMV among patients with PM/PTX was 67.9% (36/53) (OR 7.46; 95% CI 4.12-13.50; p < .001), while it was 22.1% (262/1185) among patients without PM and PTX. Mortality among patients with PM/PTX was 33.9% (19/56) (OR 4.39; 95% CI 2.45-7.85; p < .001), while it was 10.5% (131/1250) among patients without PM and PTX.
Conclusions: In patients admitted to the IRCU for severe SARS-CoV-2 pneumonia requiring NIRS, incidences of PM/PTX, PM, PTX, and PM + PTX were observed to be 4.3%, 3.8%, 1.6%, and 1.1%, respectively. Most patients with PM/PTX had HFNC + CPAP/BiPAP as the NIRS device, much more frequently than patients without PM and PTX. The probabilities of IMV and death among patients with PM/PTX were 64.3% and 33.9%, respectively, higher than those observed in patients without PM and PTX, which were 21.0% and 10.5%, respectively.
Keywords: COVID-19; SARS-CoV-2 pneumonia; incidence; intermediate respiratory care unit; invasive mechanical ventilation; mortality; noninvasive respiratory support; pneumomediastinum; pneumothorax.
. 2023 Jun 12;8850666231180165.
doi: 10.1177/08850666231180165. Online ahead of print. Severe SARS-CoV-2 Pneumonia and Pneumomediastinum/Pneumothorax: A Prospective Observational Study in an Intermediate Respiratory Care Unit
Miguel Lorente-González[SUP] 1 [/SUP], José Rafael Terán-Tinedo[SUP] 1 [/SUP], Annette Zevallos-Villegas[SUP] 1 [/SUP], Daniel Laorden[SUP] 1 [/SUP], Pablo Mariscal-Aguilar[SUP] 1 [/SUP], Miguel Suárez-Ortiz[SUP] 1 [/SUP], Eduardo Cano-Sanz[SUP] 2 [/SUP], María Ángeles Ortega-Fraile[SUP] 2 [/SUP], Joaquín Hernández-Núñez[SUP] 2 [/SUP], Adalgisa Falcone[SUP] 1 [/SUP], Elena María Saiz-Lou[SUP] 3 [/SUP], María Cristina Plaza-Moreno[SUP] 1 [/SUP], Christian García-Fadul[SUP] 1 [/SUP], Manuel Valle-Falcones[SUP] 1 [/SUP], Ana Sánchez-Azofra[SUP] 1 [/SUP], Clotilde Funes-Moreno[SUP] 4 [/SUP], Isabel De-La-Calle-Gil[SUP] 4 [/SUP], Rosalía Navarro-Casado[SUP] 4 [/SUP], Daniel Carballo-López[SUP] 4 [/SUP], Soraya Gholamian-Ovejero[SUP] 4 [/SUP], Berta Gallego-Rodríguez[SUP] 4 [/SUP], Tomás Villén-Villegas[SUP] 2 [/SUP], Pedro Landete[SUP] 1 5 [/SUP]
Affiliations
- PMID: 37306158
- DOI: 10.1177/08850666231180165
Introduction: The occurrence of pneumomediastinum (PM) and/or pneumothorax (PTX) in patients with severe pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was evaluated.
Methods: This was a prospective observational study conducted in patients admitted to the intermediate respiratory care unit (IRCU) of a COVID-19 monographic hospital in Madrid (Spain) between December 14, 2020 and September 28, 2021. All patients had a diagnosis of severe SARS-CoV-2 pneumonia and required noninvasive respiratory support (NIRS): high-flow nasal cannula (HFNC), continuous positive airway pressure (CPAP), and bilevel positive airway pressure (BiPAP). The incidences of PM and/or PTX, overall and by NIRS, and their impact on the probabilities of invasive mechanical ventilation (IMV) and death were studied.
Results: A total of 1306 patients were included. 4.3% (56/1306) developed PM/PTX, 3.8% (50/1306) PM, 1.6% (21/1306) PTX, and 1.1% (15/1306) PM + PTX. 16.1% (9/56) of patients with PM/PTX had HFNC alone, while 83.9% (47/56) had HFNC + CPAP/BiPAP. In comparison, 41.7% (521/1250) of patients without PM and PTX had HFNC alone (odds ratio [OR] 0.27; 95% confidence interval [95% CI] 0.13-0.55; p < .001), while 58.3% (729/1250) had HFNC + CPAP/BiPAP (OR 3.73; 95% CI 1.81-7.68; p < .001). The probability of needing IMV among patients with PM/PTX was 67.9% (36/53) (OR 7.46; 95% CI 4.12-13.50; p < .001), while it was 22.1% (262/1185) among patients without PM and PTX. Mortality among patients with PM/PTX was 33.9% (19/56) (OR 4.39; 95% CI 2.45-7.85; p < .001), while it was 10.5% (131/1250) among patients without PM and PTX.
Conclusions: In patients admitted to the IRCU for severe SARS-CoV-2 pneumonia requiring NIRS, incidences of PM/PTX, PM, PTX, and PM + PTX were observed to be 4.3%, 3.8%, 1.6%, and 1.1%, respectively. Most patients with PM/PTX had HFNC + CPAP/BiPAP as the NIRS device, much more frequently than patients without PM and PTX. The probabilities of IMV and death among patients with PM/PTX were 64.3% and 33.9%, respectively, higher than those observed in patients without PM and PTX, which were 21.0% and 10.5%, respectively.
Keywords: COVID-19; SARS-CoV-2 pneumonia; incidence; intermediate respiratory care unit; invasive mechanical ventilation; mortality; noninvasive respiratory support; pneumomediastinum; pneumothorax.